Filtered By:
Source: Circulation
Condition: Hemorrhagic Stroke
This page shows you your search results in order of date.
Order by Relevance | Date
Total 78 results found since Jan 2013.
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction in STREAM-2: A Randomized, Open-Label Trial
CONCLUSIONS: Halving the dose of tenecteplase in a pharmaco-invasive strategy in this early-presenting, older STEMI population was associated with electrocardiographic changes that were at least comparable to those after primary PCI. Similar clinical efficacy and angiographic end points occurred in both treatment groups. The risk of intracranial hemorrhage was higher with half-dose tenecteplase than with primary PCI. If timely PCI is unavailable, this pharmaco-invasive strategy is a reasonable alternative, provided that contraindications to fibrinolysis are observed and excess anticoagulation is avoided.REGISTRATION: URL: ...
Source: Circulation - July 13, 2023 Category: Cardiology Authors: Frans Van de Werf Arsen D Risti ć Oleg V Averkov Alexandra AriasMendoza Yves Lambert Jos é F Kerr Saraiva Pablo Sepulveda Fernando Rosell-Ortiz John K French Ljilja B Musi ć Katleen Vandenberghe Kris Bogaerts Cynthia M Westerhout Alain Pag ès Thierry Source Type: research
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
CONCLUSIONS: Standard-dose DOACs are safer and more effective than warfarin down to a CrCl of at least 25 mL/min. Lower-dose DOACs do not significantly lower the incidence of bleeding or ICH compared with standard-dose DOACs but are associated with a higher incidence of S/SE and death. These findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.PMID:37042255 | DOI:10.1161/CIRCULATIONAHA.122.062752
Source: Circulation - April 12, 2023 Category: Cardiology Authors: Josephine Harrington Anthony P Carnicelli Kaiyuan Hua Lars Wallentin Manesh R Patel Stefan H Hohnloser Robert P Giugliano Keith A A Fox Ziad Hijazi Renato D Lopes Sean D Pokorney Hwanhee Hong Christopher B Granger Source Type: research
Pharmacology and Clinical Development of Factor XI Inhibitors
This article reviews the rationale, pharmacology, results of medium or small phase 2 studies, and future perspectives of drugs inhibiting FXI.PMID:36913497 | DOI:10.1161/CIRCULATIONAHA.122.062353
Source: Circulation - March 13, 2023 Category: Cardiology Authors: Antonio Greco Claudio Laudani Marco Spagnolo Federica Agnello Denise Cristiana Faro Simone Finocchiaro Marco Legnazzi Maria Sara Mauro Placido Maria Mazzone Giovanni Occhipinti Carla Rochira Lorenzo Scalia Davide Capodanno Source Type: research
Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE
CONCLUSIONS: In patients with atherosclerotic cardiovascular disease, long-term achievement of lower LDL-C levels, down to <20 mg/dL (<0.5 mmol/L), was associated with a lower risk of cardiovascular outcomes with no significant safety concerns.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01764633.PMID:36779348 | DOI:10.1161/CIRCULATIONAHA.122.063399
Source: Circulation - February 13, 2023 Category: Cardiology Authors: Prakriti Gaba Michelle L O'Donoghue Jeong-Gun Park Stephen D Wiviott Dan Atar Julia F Kuder KyungAh Im Sabina A Murphy Gaetano M De Ferrari Zbigniew A Gaciong Kalman Toth Ioanna Gouni-Berthold Jose Lopez-Miranda Fran çois Schiele Fran çois Mach Jose H F Source Type: research
Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
CONCLUSIONS: Early initiation was noninferior to delayed start of NOAC after acute ischemic stroke in patients with atrial fibrillation. Numerically lower rates of ischemic stroke and death and the absence of symptomatic intracerebral hemorrhages implied that the early start of NOAC was safe and should be considered for acute secondary stroke prevention in patients eligible for NOAC treatment.REGISTRATION: URL: http://www.CLINICALTRIALS: gov; Unique identifier: NCT02961348.PMID:36065821 | DOI:10.1161/CIRCULATIONAHA.122.060666
Source: Circulation - September 6, 2022 Category: Cardiology Authors: Jonas Oldgren Signild Åsberg Ziad Hijazi Per Wester Maria Bertilsson Bo Norrving National TIMING Collaborators Source Type: research
Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
CONCLUSIONS: Long-term LDL-C lowering with evolocumab was associated with persistently low rates of adverse events for over >8 years that did not exceed those observed in the original placebo arm during the parent study and led to further reductions in cardiovascular events compared with delayed treatment initiation.PMID:36031810 | DOI:10.1161/CIRCULATIONAHA.122.061620
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Michelle L O'Donoghue Robert P Giugliano Stephen D Wiviott Dan Atar Anthony C Keech Julia F Kuder KyungAh Im Sabina A Murphy Jose H Flores-Arredondo J Antonio G Lopez Mary Elliott-Davey Bei Wang Maria Laura Monsalvo Siddique Abbasi Marc S Sabatine Source Type: research
Association Between Endovascular Therapy Time to Treatment and Outcomes in Patients with Basilar Artery Occlusion
CONCLUSIONS: Among patients receiving EVT for BAO, faster treatment from symptom onset was associated with improved outcomes. These findings support efforts to achieve rapid treatment with EVT for those with BAO.PMID:35050693 | DOI:10.1161/CIRCULATIONAHA.121.056554
Source: Circulation - January 20, 2022 Category: Cardiology Authors: Raed A Joundi Jie-Lena Sun Ying Xian Brooke Alhanti Raul G Nogueira Deepak L Bhatt Gregg C Fonarow Jeffrey Saver Lee H Schwamm Eric E Smith Source Type: research
